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Abstract
Background: Postoperative pulmonary complications (PPC) may result in longer duration of in-hospital stay and
even mortality. Both thoracic surgery and intraoperative mechanical ventilation settings add considerably to the risk
of PPC. It is unclear if one-lung ventilation (OLV) for thoracic surgery with a strategy of intraoperative high positive
end-expiratory pressure (PEEP) and recruitment maneuvers (RM) reduces PPC, compared to low PEEP without RM.
Methods: PROTHOR is an international, multicenter, randomized, controlled, assessor-blinded, two-arm trial initiated by
investigators of the PROtective VEntilation NETwork. In total, 2378 patients will be randomly assigned to one of two
different intraoperative mechanical ventilation strategies. Investigators screen patients aged 18 years or older, scheduled
for open thoracic or video-assisted thoracoscopic surgery under general anesthesia requiring OLV, with a maximal body
mass index of 35 kg/m2, and a planned duration of surgery of more than 60min. Further, the expected duration of OLV
shall be longer than two-lung ventilation, and lung separation is planned with a double lumen tube. Patients will be
randomly assigned to PEEP of 10 cmH2O with lung RM, or PEEP of 5 cmH2O without RM. During two-lung ventilation
tidal volume is set at 7mL/kg predicted body weight and, during OLV, it will be decreased to 5mL/kg. The occurrence of
PPC will be recorded as a collapsed composite of single adverse pulmonary events and represents the primary endpoint.
Discussion: PROTHOR is the first randomized controlled trial in patients undergoing thoracic surgery with OLV that is
adequately powered to compare the effects of intraoperative high PEEP with RM versus low PEEP without RM on PPC.
The results of the PROTHOR trial will support anesthesiologists in their decision to set intraoperative PEEP during
protective ventilation for OLV in thoracic surgery.
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Background
Postoperative pulmonary complications (PPC) increase
morbidity, resulting in longer duration of in-hospital stay
and even increased mortality [1–3]. Several independent
risk factors for the development of PPC have been iden-
tified [4], including patients’ health conditions, surgical
approaches, and anesthetic management [5]. In addition,
thoracic surgery [3] and intraoperative mechanical venti-
lation settings [2] add considerably to the risk of PPC.
Experimental [6–8] and clinical evidence [9–11] show
that mechanical ventilation has the potential to aggravate
or even initiate lung injury (so called ventilator-induced
lung injury; VILI). Repetitive collapse/reopening of lung
units (atelectrauma), overdistension of lung units (volu-
trauma), and increased airway pressures (barotrauma) are
possible mechanisms underlying VILI [12–14]. While
positive end-expiratory pressure (PEEP) can minimize
atelectrauma and low tidal volumes (VT) reduce volu-
trauma, ventilation at low airway pressures may decrease
barotrauma.
A metanalysis showed that use of low VT is associ-
ated with favorable outcomes in patients without in-
jured lungs [15]. More recently, another meta-analysis
showed a decrease in the incidence of lung injury,
pulmonary infection, and atelectasis in patients re-
ceiving intraoperative mechanical ventilation with low
VT and PEEP [16]. In patients undergoing abdominal
surgery, an intraoperative ventilation strategy with
low VT and PEEP improved postoperative lung func-
tion [17] and even outcome [16]. In contrast, when
low VT is used, the use of high PEEP combined with
recruitment maneuvers (RM), as compared to low
PEEP without RM, does not add to protection against
PPC [18]. To our knowledge, the potential of high
PEEP and RM during one-lung ventilation (OLV) for
thoracic surgery to reduce PPC has not been investi-
gated in adequately powered trials [19, 20]. Due to
mediastinal displacement, surgical manipulation, and
chest immobilization, pressures in the dependent lung
[21] and atelectasis formation are higher during thor-
acic surgery as compared with the other types of sur-
geries [22]. Thus, OLV might benefit from mechanical
ventilation with high PEEP and RM.
In view of these facts, we designed the PROtective
ventilation with high versus low PEEP during OLV for
THORacic surgery (PROTHOR) trial. We hypothesized
that intraoperative mechanical ventilation using high
PEEP with periodic RM, as compared to low PEEP with-
out RM, will prevent PPC in patients undergoing thor-
acic surgery with OLV.
Methods
Objectives and design
PROTHOR is an international, multicenter, randomized,
controlled, assessor-blinded, two-arm trial initiated by
investigators of the PROtective VEntilation NETwork
(http://provenet.eu). In total, 2378 patients will be ran-
domly assigned to one of two different intraoperative
mechanical ventilation strategies (see CONSORT dia-
gram, Fig. 1).
The PROTHOR trial tests the hypothesis that, in pa-
tients undergoing thoracic surgery under OLV, high
levels of PEEP and RM, as compared with low levels of
PEEP without RM, reduce PPC.
Study population
Investigators screen patients aged 18 years or above
scheduled for open thoracic or video-assisted thora-
coscopic surgery under general anesthesia requiring
OLV, with a maximal body mass index of 35 kg/m2,
and a planned duration of surgery of more than 60
min. Further, the expected duration of OLV shall be
longer than two-lung ventilation (TLV), and lung
separation is planned with a double lumen tube.
The number of patients meeting these enrollment
criteria will be recorded by means of a screening
log file.
Patients are excluded if they have documented
chronic obstructive pulmonary disease (COPD)
GOLD grades III and IV, lung fibrosis, documented
bullae, severe emphysema or pneumothorax; uncon-
trolled asthma; heart failure New York Heart Associ-
ation grade 3 and 4 or coronary heart disease
Canadian Cardiovascular Society grade 3 and 4; pre-
vious lung surgery; at-rest documented mean pul-
monary arterial hypertension > 25 mmHg, or systolic
pulmonary arterial pressure > 40 mmHg (as estimated
by ultrasound); documented or suspected neuromus-
cular disease (e.g., thymoma, myasthenia, myop-
athies, muscular dystrophies); are planned for
mechanical ventilation after surgery; are planned for
bilateral procedures; undergo lung separation with a
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method other than double lumen tube; are operated
in prone position; show persistent hemodynamic in-
stability or intractable shock (as judged by the treat-
ing physician); have intracranial injury or tumor; are
enrolled in other interventional studies or refuse in-
formed consent; are pregnant (excluded by anam-
nesis and/or laboratory analysis); have documented
preoperative hypercapnia > 45 mmHg (6 kPa, kPa);
are planned for esophagectomy, pleural surgery only,
sympathectomy surgery only, chest wall surgery only,
mediastinal surgery only, and lung transplantation
without surgical treatment of the lung tissue. Add-
itionally, patients will be excluded if aspiration,
moderate respiratory failure, infiltrates, pulmonary
infection, atelectasis, cardiopulmonary edema, pleural
effusion, pneumothorax, pulmonary embolism,
purulent pleurisy, or lung hemorrhage are diagnosed
before surgery.
Intervention
Mechanical ventilation
Mechanical ventilation is applied in volume-controlled
mode. Following intubation, PEEP is set according to the
randomization group, i.e., 5 cmH2O in the low PEEP
level group and 10 cmH2O in the high PEEP level group.
In both groups, the PEEP is maintained unchanged until
extubation, unless rescue for hypoxemia mandates ad-
justments. If auto-PEEP is suspected, the respiratory rate
or inspiratory to expiratory time (I:E) ratio may be chan-
ged at discretion of the treating physician.
In the high PEEP group, RM are performed at the fol-
lowing occasions:
Fig. 1 CONSORT Diagram for the PROTHOR trial. OLV one-lung ventilation, PEEP positive end-expiratory airway pressure
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 after bronchoscopy or disconnection of the
ventilated lung from the mechanical ventilator
 at start of OLV
 every 1 hour during OLV
 after re-expansion of the non-dependent lung to re-
sume TLV
 end of surgery in supine position
During TLV, VT is set at 7 mL/kg predicted body
weight (PBW). The PBW is calculated according to a
predefined formula, as follows: 50 + 0.91 x (height in cm
– 152.4) for males and 45.5 + 0.91 x (height in cm –
152.4) for females [23].
During OLV, VT will be decreased to 5 mL/kg PBW,
while keeping other settings initially unchanged. If peak
pressure > 40 cmH2O, or plateau pressure > 30 cmH2O,
the I:E ratio is first changed to 1:1. Thereafter, VT can be
decreased to 4 mL/kg PBW.
Further settings are fraction of inspiratory oxygen
(FIO2) ≥ 0.4, I:E 1:1 to 1:2, and respiratory rate adjusted
to normocapnia (partial arterial carbon dioxide pressure
(PaCO2) between 35 and 45 mmHg).
RM and lung expansion maneuvers
Standardized RM (Fig. 2) are performed with stepwise in-
crease of VT in volume-controlled ventilation (Table 1).
A lung re-expansion maneuver of the non-ventilated
lung may be necessary in both groups due to different
reasons, including detection of air leaks by request of
surgeons, as part of a rescue strategy due to hypoxemia,
or before switching from OLV to TLV to re-expand the
collapsed lung. Such a maneuver is performed in a
hemodynamically stable patient (as judged by the
anesthesiologist) and in agreement with the surgeon. To
obtain standardization among centers, re-expansion ma-
neuvers of non-ventilated lungs are performed with con-
tinuous positive airway pressure (Table 1).
Rescue strategies for intraoperative hypoxemia and
intraoperative hypercapnia
If hypoxemia, defined as peripheral oxygen saturation
(SpO2) < 90% for longer than 1min occurs, rescue
should be performed (Table 2). If hypercapnia (PaCO2 >
60mmHg) with respiratory acidosis (pHa < 7.20) occurs
during OLV, different steps are applied in the high and
low PEEP groups (Table 2).
Standard procedures
To avoid interference with the trial intervention, routine
elements of perioperative anesthesia care (including gen-
eral anesthesia, postoperative pain management, phy-
siotherapeutic procedures, and fluid management) are
performed according to each center’s specific expertise
and clinical routine. The following approaches are sug-
gested (not mandatory) for anesthetic management:
 Use of inhaled isoflurane, desflurane or sevoflurane,
intravenous propofol, remifentanil or sufentanil, and
cisatracurium, atracurium, vecuronium, or
rocuronium (as required)
 Use of sugammadex or a balanced solution of
prostigmine, or neostigmine and atropine or
glycopyrrolate for reversal of muscle relaxation,
guided by neuromuscular function monitoring (for
example, train-of-four stimulation)
Fig. 2 Standardized lung recruitment maneuver in the high PEEP group. Ppeak peak airway pressure, Pplat plateau airway pressure, PEEP positive end-
expiratory airway pressure, VT tidal volume normalized for predicted body weight, RR respiratory rate, I:E ratio between inspiratory and expiratory time
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Table 1 Recruitment and lung re-expansion maneuver steps
Recruitment
maneuver
1. Increase FIO2 to 1.0
2. Set peak inspiratory pressure limit to 45 cmH2O
3. Set respiratory rate to six breaths/min
4. Set I:E ratio to 1:1
5. Increase VT in steps of approximately 2 mL/kg PBW until plateau pressure reaches 30–40 cmH2O
6. If the maximum VT allowed by the anesthesia ventilator is achieved and the plateau pressure is lower than 30 cmH2O,
increase the PEEP as needed, to a maximum of 20 cmH2O
7. Allow three breaths while maintaining plateau pressure of 30–40 cmH2O
8. Set VT, PEEP, respiratory rate, and I:E ratio back to pre-recruitment values
Lung re-expansion
maneuver
1. Keep the non-ventilated under visual inspection, whenever possible
2. Connect the CPAP device with adequate oxygen flow (FIO2 1.0) to the non-ventilated lung
3. Set CPAP to 10 cmH2O during 20 s
4. Set CPAP to 15 cmH2O during 20 s
5. Set CPAP to 20 cmH2O during 20 s
6. If performed as part of a rescue therapy for hypoxemia and oxygenation has been restored, reduce CPAP as soon as possible
to 10 cmH2O, or 5 cmH2O, or disconnect the CPAP device
RM recruitment maneuver, FIO2 inspiratory fraction of oxygen, I:E ratio inspiratory to expiratory ratio, VT tidal volume, PBW predicted body weight, PEEP positive
end-expiratory pressure, CPAP continuous positive airway pressure
Table 2 Rescue strategies for intraoperative hypoxemia and hypercapnia
If hypoxemia occurs in the high PEEP group
during TLV
1. Apply RM
2. Increase PEEP to 12 cmH2O and apply RM
3. Increase FIO2 in steps of 0.1 until 1.0
4. Consider stepwise decrease of PEEP down to 8 cmH2O
If hypoxemia occurs in the low PEEP group
during TLV
1. Increase FIO2 in steps of 0.1 until 1.0
2. Apply RM
3. Increase PEEP to 6 cmH2O
4. Apply RM
5. Increase PEEP to 7 cmH2O
6. Apply RM
If hypoxemia occurs in the high PEEP group
during OLV
1. Apply RM
2. Increase PEEP to 12 cmH2O and apply RM
3. Increase FIO2 in steps of 0.1 up to 1.0
4. Apply oxygen to the non-ventilated lung, consider using CPAP (see lung re-expansion
maneuver) up to a pressure of 20 cmH2O, or selective oxygen insufflation via fiberscope
5. Consider stepwise decrease of PEEP of the ventilated lung to 8 cmH2O
6. Consider surgical intervention (e.g., clamping of the pulmonary artery by surgeon)
7. Consider administration of inhaled nitric oxide or prostacyclin, or intravenous almitrine
(provided the drug is approved in your country/institution)
8. Switch to TLV
If hypoxemia occurs in the low PEEP group
during OLV
1. Increase FIO2 in steps of 0.1 up to 1.0
2. Apply oxygen to the non-ventilated lung, consider CPAP therapy (re-expansion of the
non-ventilated lung) up to a pressure of 20 cmH2O, or selective oxygen insufflation
via fiberscope
3. Apply RM to the ventilated lung
4. Increase PEEP to 6 cmH2O
5. Apply RM to the ventilated lung
6. Increase PEEP to 7 cmH2O
7. Apply RM to the ventilated lung
8. Consider surgical intervention (e.g., clamping of the pulmonary artery by surgeon)
9. Consider administration of inhaled nitric oxide or prostacyclin, or intravenous
almitrine (provided the drug is approved in your country/institution)
10. Switch to TLV
If hypercapnia (PaCO2 > 60 mmHg) with respiratory
acidosis (pHa < 7.20) occurs during OLV, these steps
are applied in the high and low PEEP groups
1. Increase the respiratory rate (maximum 30/min, while minimizing intrinsic PEEP)
2. Increase VT stepwise up to 7 mL/kg PBW
3. Switch to TLV
RM recruitment maneuver, PEEP positive end-expiratory pressure, TLV two lung ventilation, FIO2 inspiratory fraction of oxygen, OLV one lung ventilation, CPAP
continuous positive airway pressure, PaCO2 arterial partial pressure of carbon dioxide, pHa arterial pH value, VT tidal volume, PBW predicted body weight
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 For postoperative pain management to achieve a
VAS pain score below 3 use regional anesthesia,
including epidural, paravertebral, and intercostal
blockade, and consideration of indications, contra-
indications, and local preferences is encouraged, but
not obligatory
 Use of physiotherapy by early mobilization, deep
breathing exercises with and without incentive
spirometry, and stimulation of cough in the
postoperative period
 Avoid fluid underload and overload
 Use of invasive measurement of arterial blood
pressure whenever indicated
 Use of appropriate prophylactic antibiotics whenever
indicated
 Use of gastric tubes, urinary bladder catheters, and
more invasive monitoring according to individual
needs, as well as local practice and/or guidelines
In addition, the study protocol stresses that routine in-
traoperative monitoring should include measurements of
blood pressure, pulse oximetry, end-tidal carbon dioxide
fraction, and electrocardiography. Every patient should
receive at least one peripheral venous line to allow ad-
equate fluid resuscitation during the study period. Other
procedures should follow the Safe Surgery Checklist of
the World Health Organization as published
(www.who.int/patientsafety/safesurgery/en/index.html).
Minimization of bias
Allocation sequence is computer generated (nQuery
Version 4.0) using permuted blocks with random sizes
of 4, 6, and 8. Allocation is stratified per center with an
allocation ratio of 1:1 for each group. The process of se-
quence generation and storage is managed by an inde-
pendent database manager not involved in patient care.
Randomization is then performed patient-by-patient
using a web interface (REDcap™).
At each study site, at least two assessors are involved
with the study. One assessor is involved with the intra-
operative mechanical ventilation strategy and performs
randomization as well as the interventions defined in the
protocol. A second assessor, who is blinded to
randomization, performs postoperative visits and assess-
ment of primary and secondary endpoints.
Study endpoints
The primary endpoint is a collapsed composite of all
PPC developing within the first 5 postoperative days.
With this approach each complication has an equal
weight. Patients who develop a least one complication
are considered as meeting the primary endpoint.
PPC are defined as follows:
 aspiration pneumonitis (defined as respiratory failure
after the inhalation of regurgitated gastric contents)
 moderate respiratory failure (SpO2 < 90% or
PaO2 < 60 mmHg for 10 min in room air,
responding to oxygen > 2 L/min)
 severe respiratory failure (need for non-invasive or
invasive mechanical ventilation due to poor
oxygenation)
 adult respiratory distress syndrome (mild, moderate,
or severe according to the Berlin definition [24])
 pulmonary infection (defined as new or progressive
radiographic infiltrate plus at least two of the
following: antibiotic treatment, tympanic
temperature > 38 °C, leukocytosis or leucopenia
(white blood cell (WBC) count < 4000 cells/mm3
or > 12,000 cells/mm3) and/or purulent secretions)
 atelectasis (suggested by lung opacification with shift
of the mediastinum, hilum, or hemidiaphragm
towards the affected area, and compensatory over-
inflation in the adjacent non-atelectatic lung)
 cardiopulmonary edema (defined as clinical signs of
congestion, including dyspnea, edema, rales, and
jugular venous distention, with the chest x-ray dem-
onstrating increase in vascular markings and diffuse
alveolar interstitial infiltrates)
 pleural effusion (chest x-ray demonstrating blunting
of the costophrenic angle, loss of the sharp silhouette
of the ipsilateral hemidiaphragm in upright position,
evidence of displacement of adjacent anatomical
structures, or (in supine position) a hazy opacity in
one hemithorax with preserved vascular shadows)
 pneumothorax (defined as air in the pleural space
with no vascular bed surrounding the visceral pleura)
 pulmonary infiltrates (chest x-ray demonstrating
new monolateral or bilateral infiltrate without other
clinical signs)
 prolonged air leakage (air leak requiring at least 7
days of postoperative chest tube drainage)
 purulent pleuritic (receiving antibiotics for a
suspected infection, as far as not explained by the
preoperative patient condition alone)
 pulmonary embolism (as documented by pulmonary
arteriogram or autopsy, or supported by ventilation/
perfusion radioisotope scans, or documented by
echocardiography and receiving specific therapy)
 lung hemorrhage (bleeding through the chest tubes
requiring reoperation, or three or more red blood
cell packs)
Secondary clinical endpoints include:
 extended PPC, including bronchospasm (defined
as newly detected expiratory wheezing treated
with bronchodilators) or mild respiratory failure
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(SpO2 < 90% or PaO2 < 60 mmHg for 10 min in
room air, responding to oxygen ≤ 2 L/min)
 intraoperative complications (use of continuous
positive airway pressure for the non-ventilated lung,
use of inhaled nitric oxide/prostacycline, use of se-
lective fiberoscope insufflation, hypotension unre-
sponsive to fluids and/or vasoactive drugs, new
arrhythmias unresponsive to intervention, need for
high dosage of vasoactive drugs (a dosage at the tol-
erance limit of the treating physician), need for
massive transfusion, life-threatening surgical compli-
cation including major bleeding, tension pneumo-
thorax, intracranial injury, hypoxemia and
hypercapnia rescue maneuvers, deviation from pre-
scribed PEEP or VT)
 postoperative extrapulmonary complications
 need for unexpected intensive care unit admission
or readmission
 number of hospital-free days at day 28
 90-day survival
 in-hospital survival
 arterial blood gas analysis during surgery (PaO2,
PaCO2, pHa)
 any postoperative respiratory intervention (new
requirement of non-invasive ventilation or mechan-
ical ventilation)
Postoperative extrapulmonary complications include:
 systemic inflammatory response syndrome (presence
of two or more of the following findings: body
temperature < 36 °C or > 38 °C, heart rate > 90 beats
per minute, respiratory rate > 20 breaths per minute
or, on blood gas, a PaCO2 < 32 mmHg (4.3 kPa),
WBC count < 4000 cells/mm3 or > 12,000 cells/mm3,
or > 10% band forms)
 sepsis (systemic inflammatory response syndrome in
response to a confirmed infectious process; infection
can be suspected or proven (by culture, stain, or
polymerase chain reaction), or a clinical syndrome
pathognomonic for infection)
 specific evidence for infection includes WBCs in
normally sterile fluid (such as urine or cerebrospinal
fluid, evidence of a perforated viscera (free air on
abdominal x-ray or computer tomography scan,
signs of acute peritonitis), abnormal chest x-ray con-
sistent with pneumonia (with focal opacification), or
petechiae, purpura, or purpura fulminans)
 severe sepsis (sepsis with organ dysfunction,
hypoperfusion, or hypotension), septic shock (sepsis
with refractory arterial hypotension or
hypoperfusion abnormalities in spite of adequate
fluid resuscitation); signs of systemic hypoperfusion
may be either end-organ dysfunction or serum
lactate greater than 4 mmol/dL, other signs include
oliguria and altered mental status
 septic shock id defined as sepsis plus hypotension
after aggressive fluid resuscitation, typically upwards
of 6 L or 40 mL/kg of crystalloid
 extra-pulmonary infection (wound infection + any
other infection)
 coma (Glasgow Coma Score < 8 in the absence of
therapeutic coma or sedation)
 acute myocardial infarction (detection of rise and/or
fall of cardiac markers (preferably troponin) with at
least one value above the 99th percentile of the
upper reference limit, together with symptoms of
ischemia, electrocardiography changes indicative of
new ischemia, development of pathological Q-waves,
or imaging evidence of new loss of viable myocar-
dium or new regional wall motion abnormality or
sudden unexpected cardiac death, involving cardiac
arrest with symptoms suggestive of cardiac ischemia
(but death occurring before the appearance of car-
diac markers in blood))
 acute renal failure (renal failure documented as
follows: Risk: increased creatinine × 1.5 or
glomerular filtration rate (GFR) decrease > 25% or
urine output (UO) < 0.5 mL/kg/h × 6 h; Injury:
increased creatinine × 2 or GFR decrease > 50% or
UO < 0.5 mL/kg/h × 12 h; Failure: increased
creatinine × 3 or GFR decrease > 75% or UO < 0.3
mL/kg/h × 24 h or anuria × 12 h; Loss: persistent
acute renal failure = complete loss of kidney function
> 4 weeks)
 disseminated intravascular coagulation (score
documented as follows: platelet count < 50 (2 points),
< 100 (1 point), or ≥ 100 (0 points); D-dimer > 4 μg/mL
(2 points), > 0.39 μg/mL (1 point) or ≤ 0.39 μg/mL
(0 points); prothrombin time > 20.5 s (2 points), > 17.5 s
(1 point), or ≤ 17.5 s (0 points), if ≥ 5 points: overt
disseminated intravascular coagulation)
 stroke (new clinical signs of stroke lasting longer
than 24 h and corresponding findings in radiologic
imaging)
 hepatic failure (hepatic failure during short-term
follow-up (5 postoperative days) is considered as fol-
lows: bilirubin serum level > 2 mg/dL + elevation of
alanine amino transferase/aspartate amino transferase
+ lactate dehydrogenase × 2 above normal values; dur-
ing long-term follow-up (until postoperative day 90)
at new presence of hepatic encephalopathy and coag-
ulopathy (international normalized ratio (INR) > 1.5)
within 8 weeks after initial signs of liver injury (e.g.,
jaundice) without evidence for chronic liver disease)
 gastrointestinal failure (any type of gastrointestinal
bleeding or gastrointestinal failure score
documented as follows: 0 = normal gastrointestinal
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function; 1 = enteral feeding with under 50% of
calculated needs or no feeding 3 days after
abdominal surgery; 2 = food intolerance or intra-
abdominal hypertension; 3 = food intolerance and
intra-abdominal hypertension; and 4 = abdominal
compartment syndrome)
At the discretion of participating centers, blood and
urine samples are collected preoperatively as well as dir-
ectly postoperative and on the postoperative days 1–5.
Samples will be analyzed centrally for systemic markers
of inflammation and coagulation (including but not lim-
ited to interleukins 6 and 8, thrombin-antithrombin,
protein C, and plasminogen activator inhibitor-1) as well
as systemic markers of injury to the lungs (including but
not limited to plasma E-cadherin, soluble receptor for
advanced glycation end-products, surfactant proteins A
and D, and distal organs, including renal injury (includ-
ing but not limited to plasma/urine neutrophil
gelatinase-associated lipocalin, and cystatin C). The
standard operating procedure for collecting and process-
ing plasma and urine is available in Additional file 1.
Study visits and data collection
Patients are visited preoperatively, intraoperatively, daily
between postoperative days 1 and 5, and on discharge.
On postoperative day 90, patients are contacted by
phone (Fig. 3).
Patients are screened according to inclusion criteria.
All patients meeting the inclusion criteria are registered
in a screening log file by each center. Eligible patients
Fig. 3 Schedule of enrolment, interventions, and assessments. POD postoperative day, PEEP positive end-expiratory airway pressure, RM (lung)
recruitment maneuver, SpO2 peripheral oxygen saturation
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meeting none of the exclusion criteria are asked by the
physician for written informed consent (the consent
form and information to study patients form are avail-
able in Additional file 1).
Baseline variables are collected, including gender, age,
height, weight, ARISCAT Score, physical status accord-
ing to the American Society of Anesthesiologists, func-
tional status according to cumulated ambulation score,
metabolic equivalents, cardiovascular status (heart fail-
ure according to the New York Heart Association,
coronary heart disease according to Canadian Cardiovas-
cular Society, atrial flutter/fibrillation, arterial hyperten-
sion), pulmonary status (chronic obstructive pulmonary
disease, including steroids and/or inhalation therapy use,
respiratory infection within the last month, use of
non-invasive ventilatory support), history of obstructive
sleep apnea (including Apnea and Hypopnea index or
STOP-Bang score in patients without diagnosis of ob-
structive sleep apnea), metabolic status (diabetes melli-
tus, including data on treatment), history of active
cancer, smoking status, alcohol status, gastroesophageal
reflux, oral medication (e.g., use of antibiotics, statins,
aspirin), preoperative organ function (SpO2 in supine
position, upper body elevated 30–45 degrees breathing
room air; if possible, respiratory rate, heart rate, mean
arterial pressure, body temperature, airway secretion, in-
cluding data on purulence, visual analogue scales (1–10)
for dyspnea, thoracic rest pain and coughing pain).
Preoperative non-mandatory measurements include
spirometry (arterial partial pressure of oxygen, car-
bon dioxide and pH value, forced vital capacity
(FVC), forced expiratory volume in one second
(FEV1), Tiffeneau value (FEV1/FVC), total lung cap-
acity, diffusing capacity for carbon monoxide, and
maximal oxygen consumption), predicted postopera-
tive respiratory function (predicted postoperative
FVC, FEV1, and diffusing capacity for carbon mon-
oxide), chest x-ray (assessed for infiltrates, pleural
effusion, atelectasis, pneumothorax, and cardiopul-
monary edema) as well as routine laboratory tests
(including hemoglobin, hematocrit, WBC count,
platelet count, INR, partial thromboplastin time, cre-
atinine, blood urea nitrogen, alanine amino transfer-
ase, aspartate amino transferase, bilirubin, c-reactive
protein, and procalcitonin).
During the intraoperative visit, both surgery- as well
as anesthesia-related data are recorded, including dur-
ation of anesthesia (from intubation to extubation or exit
of operating room if on mechanical ventilation), dur-
ation of OLV and TLV, duration of surgery (from inci-
sion to closure), total blood loss, total urine output, side
of OLV and side of surgery, method of lung separation
(double lumen tube, endobronchial blocker, double
lumen tube with embedded camera), way of placement
confirmation (fiberoptic bronchoscopy, embedded cam-
era), administration of antibiotics, use of regional
anesthesia (epidural, paravertebral, other), use of
non-invasive ventilation during induction, patient pos-
ition during induction, patient temperature at the end of
surgery, monitoring of neuromuscular function during
anesthesia, use of neuromuscular blocker antagonists,
priority and type of surgery, wound classification, type of
surgical resection, patient position during surgery, esti-
mated amount of lung resection, and drugs and fluids
administered during anesthesia (e.g., anesthetics, vaso-
active drugs, transfusion).
Ventilator settings, hemodynamics, need for rescue
strategy, and adverse events (AEs) are recorded at
anesthesia induction, with the patient in final surgical
position and TLV, 10 min after OLV, hourly thereafter
during OLV, and at the end of surgery with TLV in
supine position. The routine measurements are docu-
mented first, then the gas probes are taken; thereafter,
the RM is performed in the high PEEP group.
RM are documented during the plateau phase of
the RM in the high PEEP group after bronchoscopy
or disconnection of the ventilated lung from the
mechanical ventilator, after the beginning of OLV,
every 1 hour during OLV, after re-expansion of the
non-dependent lung and resumption of TLV, and at
the end of surgery in supine position.
Clinical data, including actual organ function and
the presence of PPC, are scored during postoperative
visits on a daily basis. Additionally, secondary end-
points, such as postoperative extrapulmonary com-
plications, need for unexpected intensive care unit
admission or readmission, and any type of postoper-
ative respiratory intervention, are recorded. On day
1 after surgery, fluid and transfusion data are re-
corded in a detailed manner. Furthermore, the use
of physiotherapy, breathing exercises, antibiotics as
well as the cumulated ambulation score, status of
wound healing, postoperative nausea, and vomiting
are assessed.
Non-mandatory measures include chest x-ray, spirom-
etry, and routine laboratory tests. Patients will be visited
until discharge.
The number of hospital-free days at day 28 (including
readmission since hospital discharge) and 90-day sur-
vival are calculated. Day 90 is defined as the last day of
follow-up; accordingly, patients still admitted to hospital
will be last visited on that day.
Study dropouts
Participation in the trial is voluntary. Patients have the
right to withdraw consent to the study at any time for
any reason without any consequence for further medical
treatment. The reasons and circumstances for study
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discontinuation will be documented in the case report
form (CRF). Primarily, all data will be analyzed accord-
ing to the intention-to-treat principle. Secondarily, data
will be analyzed per-protocol.
Handling of data
The objective of the clinical data management plan is to
provide high-quality data by adopting standardized proce-
dures to minimize the number of errors and missing data
and, consequently, to generate an accurate database for
analysis. Two members of the research team perform
study monitoring. Remote monitoring is performed to sig-
nal early aberrant patterns, issues with consistency, cred-
ibility, and other anomalies. On-site assessment of
protocol adherence and completeness of the research dos-
sier will be conducted in up to 10 sites including the high-
est number of patients, and also neighbor sites to them.
Patient data are collected in pseudonymous form using
a patient (identification) number composed of six digits,
the first three of which correspond to the site ID and
the remaining digits correspond to the patient inclusion
number at the respective site. Study data are collected
and managed using REDCap™ electronic data capture
tools hosted at the Clinical Trial Coordination Center
(KKS) of the University of Dresden, Germany. REDCap™
(Research Electronic Data Capture) is a Secure Sockets
Layer encrypted, password-protected, web-based appli-
cation designed to support data capture for research
studies [25]. Full access to the final trial dataset will be
granted to selected investigators only. If a sub-study is
approved by the steering committee, access only to data
related to the sub-study will be granted to the respective
principal investigator.
Sample size calculations
For this trial, we have planned to use an adaptive trial
design, which accumulates data and uses external infor-
mation to modify aspects of the design without under-
mining the validity and integrity of the trial. The group
sequential methods design gives us the possibility for
early stopping of the study if the experimental treatment
shows a statistically significant therapeutic advantage at
an interim assessment, but also allows early stopping for
futility if the interim analysis reveals that, with high
probability, the trial will be negative (Fig. 4).
Sample size calculation was based on our primary
study endpoint, taking data collected from a subset of
patients undergoing OLV for thoracic surgery in a pro-
spective observational, multicenter, international study
(LAS VEGAS) [26] into account. LAS VEGAS showed
an incidence of approximately 23% for a PPC composite
comparable to the present definition. Assuming a signifi-
cance level of 0.05 and a power of 90% to detect the
expected difference in postoperative pulmonary compli-
cations between the high PEEP group of 17.25% and the
low PEEP group of 23% (risk ratio of 0.75), a sample size
of 2259 has been calculated. Assuming a dropout rate of
Fig. 4 Effect size (Z) according to enrollment of patients in the PROTHOR trial (including dropouts). Values of Z were obtained from an adaptive
sequential design (see text) with stopping criteria for harm, futility, and efficacy of the intervention
Kiss et al. Trials          (2019) 20:213 Page 10 of 20
5%, a total of 2378 patients have to be included in the
study.
We used the software package East® for sample size
calculations (East®, Version 6.3.1, Cytel Inc., USA). The
Difference of Proportions test has been used to compare
the independent samples from two populations (Group
Sequential Design for a Binomial Superiority Trial,
discrete endpoint two sample test, parallel design, differ-
ence of proportions, using the unpooled estimate of vari-
ance). The sample size calculation was done with the
following parameters: Superiority Design, two-sided test;
alpha 0.05; Power 0.9, allocation ratio 1; Propor-
tion1 = 0.23; Proportion2 = 0.1725; Difference in Propor-
tions = − 0.058.
We used an alpha-spending function to generate effi-
cacy boundaries and a beta-spending function to gener-
ate futility boundaries (Fig. 4; gamma family spending
function, type I error 0.05, type II error 0.1). By using a
gamma of − 4 for the alpha and gamma of − 2 for the
beta spending function we have a moderate hurdle for
early stopping for efficacy and a reasonable chance to
stop early due to futility (Table 3).
We constructed a non-binding futility boundary in
such a way that it can be overruled if desired with-
out inflating the type 1 error. This flexibility is im-
portant, since the data monitoring committee might
well prefer to keep the trial going to gather add-
itional information, despite crossing the futility
boundary.
We planned to take five interim assessments at the
data for evidence of efficacy, harm, and/or futility
with the aim of possibly stopping the trial early. The
planned number of assessments describes the num-
ber of time points, including the closing date of the
study, at which the investigator plans to analyze the
thus far collected data. The spacing of assessments
will be equal. Therefore, interim analyses will be per-
formed after 20% (476 patients), 40% (952 patients),
60% (1426 patients), 80% (1902 patients), and 100%
of patients (2378 in total) included.
Patients will be randomly assigned to one of the
two groups using a website-based data entry and
randomization platform (REDcap™, Ver 6.6.2 Vander-
bilt University, Tennessee, USA). Randomization will
be conducted using blocks of 4, 6, and 8 patients, in
aleatory fashion. Thereby, group sizes will be compar-
able at interim analyses, which will be conducted in a
group-blinded manner.
Statistical analysis
Continuous distribution of the data will be assessed by
visual inspection of histograms and D’Agostino–Pear-
son’s normality tests. For both arms, the baseline charac-
teristics will be expressed as counts and percentages,
means and standard deviations, or medians and inter-
quartile ranges whenever appropriate.
Ventilatory parameters and vital signs over the sur-
gery will be analyzed using a mixed-effect model
with repeated measures and with patients and cen-
ters as a random-effect. No or minimal losses to
follow-up for the primary and secondary outcomes
are anticipated. Complete-case analysis will be car-
ried out for all the outcomes. However, if more than
1% of missing data were found for the primary out-
come, a sensitivity analysis using multiple imputa-
tions and estimating equation methods will be
carried out.
Hypothesis tests will be two-sided with a significance
level of 5% with exception of the primary outcome, due
to the correction for the interim analyses. We will not
adjust p values for multiple comparisons. Analyses will
be performed using the R (R Core Team, 2016, Vienna,
Austria) program.
Primary outcome The effects of the intervention on
incidence of PPC will be reported as numbers and
percentages and estimated with risk ratios and 95%
confidence intervals calculated with Wald’s likelihood
ratio approximation test and with χ2 tests for hy-
pothesis testing. For the analysis of the primary
Table 3 Z-statistic boundaries and boundary crossing probabilities
Look Information
fraction
N Cumulative
alpha spent
Cumulative
beta spent
Z-efficacy/harm Z-futility Boundary crossing probabilities under H1
Efficacy Futility
1 0.2 452 0.001 0.008 ±3.252 ±0.031 0.042 0.008
2 0.4 904 0.004 0.019 ±2.986 ±0.152 0.17 0.011
3 0.6 1355 0.009 0.036 ±2.692 ±0.631 0.281 0.017
4 0.8 1807 0.022 0.062 ±2.374 ±1.344 0.263 0.026
5 1.0 2259 0.05 0.1 ±2.025 ±2.025 0.143 0.038
Values were calculated using power = 0.90, alpha = 0.05, gamma spending function − 4 for the alpha and − 2 for the beta, expected incidence of postoperative
pulmonary complications of 23% and 17.25% in the lower and higher positive end-expiratory pressure groups, respectively. Number of patients (N) is shown
without correcting for dropouts. Look, interim analysis; H1, hypothesis 1 (group difference exists)
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outcome, the result will be considered significant if
the p value is less than 0.0428 (correspondent to the
Z-value of 2.025 for efficacy or futility in the final
analysis in Table 3). Kaplan–Meier curves will be
used to report time to PPC. Curves will be com-
pared with the log-rank tests, and hazard ratios with
95% confidence intervals will be calculated with Cox
proportional hazard models without adjustment for
covariates. The proportional hazard assumptions will
be tested using scaled Schoenfeld residuals and alter-
native parametric survival models will be used if the
proportionality assumption is not sustained.
Secondary outcomes The effect of the intervention
on secondary binary outcomes will be assessed with
risk ratio and 95% confidence intervals calculated
with Wald’s likelihood ratio approximation test and
with χ2 tests for hypothesis testing. The effects of
the intervention on hospital-free days at day 28 will
be estimated with a Student t test and reported as
the mean difference between the two groups. The
consistency of the findings of the Student t-test for
the hospital-free days at day 28 will be confirmed
according to the mean ratio calculated by a general-
ized additive model considering a zero-inflated beta
distribution.
Finally, 90-day mortality will be assessed using
Kaplan–Meier curves, and hazard ratios with 95% confi-
dence intervals will be calculated with Cox proportional
hazard models without adjustment for covariates. The
proportional hazard assumptions will be tested using
scaled Schoenfeld residuals and alternative parametric
survival models will be used if the proportionality as-
sumption is not sustained.
Subgroup analyses Treatment effects on incidence of
PPC will be analyzed according to the following sub-
groups: (1) non-thoracoscopic versus thoracoscopic; (2)
lateral decubitus versus supine position; (3) baseline
SpO2 < 96% versus SpO2 ≥ 96%; and (4) COPD versus
non-COPD. The effects on subgroups will be evaluated
according to the interaction effects between each sub-
group and the study arms by generalized linear models
and presented in a forest plot.
Per-protocol analyses: The per-protocol population
will consist of patients truly ventilated with the
pre-specified protocol. Thus, patients will be ex-
cluded from this population if receiving PEEP < 10
cmH2O in the high PEEP group or PEEP > 5 cmH2O
and FIO2 < 1.0 in the low PEEP group, in any meas-
urement during the surgery.
Other exploratory analyses As a sensitivity analysis,
the effect of the intervention on the primary
outcome will be re-estimated using a generalized lin-
ear mixed-effect model with stratification variables
(center) as random effects. Since the primary out-
come of the present study is a composite one, the
choice of the statistical method is an important part
of the design because various methods provide dif-
ferent power, depending on the situation. In addition
to the standard analysis described above, the follow-
ing analyses will be performed:
 Count analysis – the number of positive
component events (i.e., ‘count’) across the
composite will be assessed. The groups will be
compared on the count using a Mann–Whitney
test, and the odds ratio with the 95% confidence
interval will be assessed with a proportional
odds logistic regression model
 Individual component analysis – the effect of the
intervention in each component will be analyzed
using a generalized linear model using a Bonferroni
correction for multiple comparisons; the 99.64%
Bonferroni-corrected confidence intervals will be re-
ported (1 – 0.05/14 = 0.9964)
 Common effect test – a multivariate (i.e.,
multiple outcomes per subject) generalized
estimating equations (GEE) model will be used
to estimate a common effect odds ratio across
the components
 Average relative effect test – the average relative
effect test will be assessed by averaging the
component-specific treatment effect from the
distinct effects model, and testing whether the
average is equal to zero; in the GEE distinct ef-
fect model, a distinct treatment effect is esti-
mated for each component
 Heterogeneity of treatment effect – heterogeneity of
treatment effect across components will be assessed
by a treatment-by-component interaction test in the
distinct effects GEE model
 Clinical severity weight – each component will
be weighted by a clinical severity weight
determined a posteriori; a multivariate (i.e.,
multiple outcomes per subject) GEE model will
be used to estimate a common effect odds ratio
across the components while applying the
severity weights
Cleaning and locking of the database The database
will be locked as soon as all data are entered and all
discrepant or missing data are resolved – or if all ef-
forts are employed and we consider that the
remaining issues cannot be fixed. In this step, the
data will be reviewed before database locking. After
that, the study database will be locked and exported
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for statistical analysis. At this stage, permission for
access to the database will be removed for all inves-
tigators, and the database will be archived.
Missing data No or minimal losses to follow-up for
the primary and secondary outcomes are anticipated.
Complete-case analysis will be carried out for all the
outcomes, that is, excluding patients with missing
data in the outcome of interest. However, if more
than 1% of missing data were found for the primary
outcome, a sensitivity analysis using multiple impu-
tations and estimating equation methods will be
performed.
Sub-studies
Participating centers are allowed to conduct
sub-studies provided that (1) no interference with
the primary protocol occurs; (2) approval by the
local institutional review board is obtained; and (3)
the steering committee accepts the proposal accord-
ing to its originality, feasibility, and importance.
Publication of sub-studies, in any form, is strictly
forbidden until the results of the primary study have
been published.
Trial organization
The trial is managed by a team consisting of the
chief investigator (Mert Sentürk), the trial coordin-
ator (Thomas Kiss), the statisticians (A. Serpa Neto,
K. Schubert and M. Kuhn), the informatics techni-
cian responsible for the web-based electronic data
capture system (Marko Kaeppler), and independent
monitors. A steering committee contributed to the
design and revision of the study, and will be respon-
sible for interpretation of data and compilation of a
resulting manuscript.
Patient data and safety is closely monitored by a
data safety and monitoring board (DSMB) that con-
sists of a chairperson (Daniel Sessler) and four fur-
ther members (Arthur Slutsky, Andreas Hoeft,
Jean-Louis Vincent, Jennifer Hunter). All AEs en-
tered into the electronic CRF within pre-specified
time frames, including severe AEs and suspected un-
expected severe adverse reactions, are monitored by
an international AE manager (Ary Serpa Neto), who
provides the DSMB with reports for review. The
DSMB further monitors the overall status of the
trial, e.g., progress of patient enrollment, general ad-
herence to protocol, and completeness of data entry.
Monitoring visits will be conducted as deemed ne-
cessary by the DSMB.
National coordinators are responsible for adminis-
tration and communication with local principal
investigators, as well as assistance during trial man-
agement and data collection.
When submitting the report on the results of the trial
for possible publication, sites will be eligible to one col-
laborative co-authorship plus a further co-authorship for
every 20 treated patients with complete datasets.
Discussion
The PROTHOR trial was designed to determine whether
a high level of PEEP with RM, as compared to low PEEP
without RM, during OLV for thoracic surgery, prevents
PPC. We opted for testing the impact of two ventilation
strategies at the same low VT in order to focus on the
independent effects of different airway pressures, espe-
cially PEEP.
The decision to use a PEEP value of 5 cmH2O in
the low PEEP group has been derived from a recent
study on the practice of intraoperative mechanical
ventilation and consensus agreement of the steering
committee [26]. In order to allow generalizability of
results and to impact on clinical practice, we opted
for a pragmatic study, where a fixed level of high
PEEP is used. The decision of using a PEEP of 10
cmH2O in the high PEEP group was based on the
fact that this value, on average, resulted in maximal
dynamic compliance of the respiratory system during
OLV in a recent study, and was accompanied by
minor variability only [27]. Additionally, this value is
only 2 cmH2O higher than needed to effectively
increase oxygenation and decrease physiological dead
space [21, 28], while avoiding substantial hemody-
namic impairment.
Even a PEEP titrated to a respiratory mechanics target,
for example, the compliance of the respiratory system
[27], represents a compromise in terms of regional over-
distension and collapse-reopening of lung units. De-
pending on regional differences, even this optimal PEEP
will not completely prevent atelectasis formation [29].
Thus, even an individualized PEEP titration in the high
PEEP group would also result in a compromise between
atelectrauma and volutrauma or barotrauma, and likely
not differ importantly from the value selected a priori in
the present trial.
The RM is based on a stepwise increase of VT and
PEEP. This maneuver allows opening of lung units
without interruption of mechanical ventilation and
ensures standardization across different centers.
Since it uses volume-controlled ventilation, virtually
all anesthesia ventilators can perform this maneuver.
The target airway pressure range for recruitment
was based on the fact that a level of 30 cmH2O was
proposed in a recent study [30], and that airway
pressure exceeding 40 cmH2O does not importantly
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contribute to open lungs even in mild acute respira-
tory distress syndrome [31].
We decided for a combination of RM and PEEP in
the high PEEP group. PEEP per se may not be
enough to open atelectatic lung units. A CT study
showed that, in patients at higher risk for develop-
ment of intraoperative atelectasis, the combination
of high PEEP and RM was able to revert lung col-
lapse, whereas isolated high PEEP or RM did not
achieve the same effect [32]. Furthermore, during
OLV, RM followed by PEEP has been shown to be
associated with a more homogenous distribution of
ventilation [33].
The inspiratory time of approximately 5 s was
chosen to allow enough pressure versus time prod-
uct (over at least three consecutive cycles) to open
atelectatic lung units. We opted for recruiting lungs
not only after intubation, but also every hour
thereafter, in order to revert possible progressive
de-recruitment at PEEP of 10 cmH2O. For both the
lower and higher PEEP groups, rescue protocols for
the progression of intraoperative hypoxemia were
defined in order to protect patients while allowing a
standardized approach that minimizes the interfer-
ence with the respective interventions. Importantly,
deviations of the protocol, even rescue due to hyp-
oxemia, are explicitly allowed, provided this in the
best interest of patients.
It is worth noting that recommendations have
been made also with regard to different phases and
aspects of the anesthetic procedure, including moni-
toring, choice of anesthetics agents, muscle paralysis
and its reversal, intravascular volume loading and
maintenance, and postoperative analgesia. However,
PROTHOR is a pragmatic study and influence on
local practice of respective sites is kept at a mini-
mum, focusing on factors that are more directly re-
lated with the hypothesis investigated.
Besides postoperative respiratory failure, several
other adverse pulmonary events seem to add to the
odds of mortality in the surgical population.
In-hospital length of stay and mortality increase with
the number of single pulmonary AEs in the postop-
erative period [3]. Therefore, in the PROTHOR trial
we opted for a binary collapsed composite of single
adverse pulmonary events as primary endpoint, des-
pite the fact that single events may differ in terms
of severity. Thus, the use of PPC as primary end-
point in the PROTHOR trial not only has clinical
relevance for the practicing anesthetist, but increases
the study power due to summation of incidences of
single AEs. In spite of this, the study analysis will
address not only the composite itself, but also the
incidence of each element separately.
Not only the respiratory but also other organ sys-
tems may be impaired in the postoperative period in
thoracic surgery patients. Thus, the analysis will also
address the impact of intraoperative mechanical ven-
tilation on single organs and a collapsed composite
of non-pulmonary AEs, namely postoperative extra-
pulmonary complications. In addition, further rele-
vant outcome measures that might be related to
PPC and postoperative extrapulmonary complica-
tions, especially the hospital-free days at day 28, will
be addressed. This outcome variable is not only a
measure of morbidity, but also has direct impact on
related health costs. Since we anticipate that, during
surgery, both the lower and the higher PEEP groups
will impact on intraoperative oxygenation, respira-
tory system mechanics, and arterial blood pressure,
intraoperative respiratory function and hemodynamic
variables will also be evaluated.
Much attention has been paid to safety in the
PROTHOR trial. Accordingly, data and patient safety
during the PROTHOR trial is closely monitored by a
DSMB. Additionally, an AE manager has been desig-
nated. A web-based electronic data capture system
(REDCap™) is used for building the database within a se-
cure system, while allowing access to the eCRF and
randomization of patients into groups.
We included complications that may be not dir-
ectly related to VILI, more specifically pulmonary
embolism and lung hemorrhage. However, the mech-
anical ventilation setting has been identified as an
independent risk factor for venous thromboembolism
[34]. Both mechanical ventilation and PEEP tend to
decrease right and left ventricular preload, especially
in the presence of hypovolemia and may increase
venous thromboembolism risk by exacerbation of
venous stasis. Recruitment maneuvers but also redis-
tribution of lung perfusion during OLV and TLV
may facilitate lung hemorrhage, which has been de-
fined as bleeding through the chest tubes requiring
reoperation or transfusion.
In summary, PROTHOR is the first randomized con-
trolled trial in patients undergoing thoracic surgery that
is adequately powered to compare the effects of intraop-
erative high PEEP with RM versus low PEEP without
RM during OLV on PPC. The results of the PROTHOR
trial will support anesthesiologists in their decision to
set intraoperative PEEP during OLV with low VT for
thoracic surgery.
Trial status
The PROTHOR trial is currently recruiting patients. Re-
cruitment started January 2017. Estimated completion
date 2021.
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Appendix
PROTHOR Investigators
Site name Collaborator
surname
Collaborator
name
Email address
Military Medical Academy, Belgrade, Serbia Neskovic Vojislava vojkan43@gmail.com
Radovic Nevena nevence1@yahoo.com
Rondovic Goran grondovic@gmail.com
Stamenkovic Dusica dusicastamenkovic@yahoo.com
Vukovic Rade radvuk@gmail.com
Zeba Snjezana snjezanazeba@hotmail.com
Department of Anaesthesiology, University Hospital Aachen,
Aachen, Germany
Rossaint Rolf rrossaint@ukaachen.de
Coburn Mark mcoburn@ukaachen.de
Kowark Ana akowark@ukaachen.de
Ziemann Sebastian sziemann@ukaachen.de
van Waesberghe Julia jvanwaesberg@ukaachen.de
Department of Anesthesiology, Academic Medical Center Amsterdam,
Amsterdam, The Netherlands
Bauer Wolfgang w.o.bauer@amc.uva.nl
Terwindt Lotte l.e.terwindt@amc.uva.nl
Attikon University Hospital, Athens, Greece Kostopanagiotou Kostas kostop@hotmail.co.uk
Kostroglou Andreas andreaskostr@gmail.com
Kyttari Katerina akyttari@gmail.com
Sidiropoulou Tatiana tatianasid@gmail.com
University Hospital Clínic de Barcelona, Spain Jiménez Andújar María-José jjimenez@somclinic.cat
López-
Baamonde
Manuel lopez10@clinic.cat
Navarro Ripoll Ricard rnavarr1@clinic.cat
Rivera Vallejo Lorena lorivera@clinic.cat
Weill Cornell Medicine, Department of Anesthesiology, New York, USA Henry Matthew mah2065@med.cornell.edu
Jegarl Anita anj2024@med.cornell.edu
Murrell Matthew mtm9006@med.cornell.edu
O’Hara Patrick pao2011@med.cornell.edu
Steinkamp Michele mls9004@med.cornell.edu
Fachkrankenhaus Coswig GmbH
Zentrum für Pneumologie, Allergologie, Beatmungsmedizin,
Thoraxchirurgie
Kraßler Jens krasslerj@fachkrankenhaus-
coswig.de
Schäfer Susanne schaefers@fachkrankenhaus-
coswig.de
Department of Anesthesiology and Intensive Care Medicine, Pulmonary
Engineering Group, University Hospital Carl Gustav Carus, Dresden, Germany
Becker Charlotte charlotte-becker@gmx.net
Birr Katja katjabirr@gmail.com
Bluth Thomas thomas.bluth@uniklinikum-
dresden.de
Gama de Abreu Marcelo mgabreu@uniklinikum-dresden.de
Hattenhauer Sara sara.hattenhauer@uniklinikum-
dresden.de
Kiss Thomas thomas.kiss@uniklinikum-
dresden.de
Scharffenberg Martin martin.scharffenberg@uniklinikum-
dresden.de
Teichmann Robert teichmannrobert@aol.com
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Wittenstein Jakob jakob.wittenstein@uniklinikum-
dresden.de
Department of Morpholo gy, Surgery and Experimental Medicine, University of
Ferrara, Ferrara, Italy
Costanza Vitali costanza.vitali@student.unife.it
Savino Spadaro savinospadaro@gmail.com
Volta Carlo
Alberto
vlc@unife.it
Ragazzi Riccardo rgc@unife.it
Calandra Camilla camilla.calandra@gmail.com
Dept of Anesthesia and Intensive Care, University of Foggia, Italy,
OO Riuniti Hospital
Mariano Karim karim_mariano@hotmail.it
Mirabella Lucia lucia.mirabella@unifg.it
Mollica Giuseppina giusymollica@virgilio.it
Montrano luigi luigi.montrano@unifg.it
Department of Anesthesiology and Intensive Care Medicine Clinic, Medical
Center - University of Freiburg, Faculty of Medicine, University of Freiburg,
Germany
Loop Torsten torsten.loop@uniklinik-freiburg.de
Semmelmann Axel axel.semmelmann@uniklinik-
freiburg.de
Wirth Steffen steffen.wirth@uniklinik-freiburg.de
Department of Anesthesiology, Fudan University Shanghai Cancer Center;
Department of Oncology, Shanghai Medical College, Fudan University,
Shanghai, China
Miao Changhong miaochh@aliyun.com
Zhong Jing ziteng1934@163.com
Lv Hu lvhu086@126.com
Wang Hui 2502425738@qq.com
Zhang Xue zx02190554@126.com
Zhang Yue aileencheung0807@163.com
IRCCS San Martino Policlinico Hospital, Genoa, Italy Pelosi Paolo ppelosi@hotmail.com
Corsi Laura corsilaura@yahoo.it
Partroniti Nicolò nicoloantonino.patroniti@unige.it
Mandelli Maura maura.mandelli@gmail.com
Bonatti Giulia giulia.bonatti@gmail.com
Simonassi Francesca francesca.simonassi@gmail.com
Gratarola Angelo a.gratarola@gmail.com
Insular Hospital, Gran Canaria, Spain Rodriguez Ruiz Juan José juanjo.rodriguezruiz@gmail.com
Socorro Tania austania@gmail.com
University Hospital of Heraklion, Heraklion, Greece Christofaki Maria mchristofaki@yahoo.gr
Nyktari Vasileia vnyktari@gmail.com
Papaioannou Alexandra papaioaa@uoc.gr
University Istanbul University, Istanbul Medical Faculty,
Department of Anaesthesiology and Intensive Care,
Istanbul, Turkey
Şentürk Nüzhet Mert senturkm@istanbul.edu.tr
Bingul Emre dremrebingul@gmail.com
Orhan Sungur Mukadder mukadder.orhan@gmail.com
Sungur Zerrin zerrin_sr@yahoo.com
University Hospital of Munich, Munich, Germany Heidegger Manuel manuel.heidegger@campus.lmu.de
Dossow Vera vera.dossow@med.uni-
muenchen.de
Jerichow Wiebke w.jerichow@web.de
Kammerer Tobias tobias.kammerer@med.uni-
muenchen.de
Richter Julia julia.richter@richtersisters.de
Schuba Barbara barbara.schuba@med.uni-
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muenchen.de
Speck Eike eike.speck@med.uni-muenchen.de
Stierle Anna-Lisa anna@stierle-mail.de
University Hospital of Prague, Prague, Czech Republic Bruthans Jan jan.bruthans@vfn.cz
Matek Jan jan.matek@vfn.cz
Michálek Pavel pavel.michalek@vfn.cz
Radboud University Medical Centre Nijmegen, The Netherlands Didden Loes loes.didden@radboudumc.nl
Hofland Jan jan.hofland@radboudumc.nl
Kuut Marieke marieke.kuut@radboudumc.nl
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